Neuroprotective and MAOB inhibitory effects of a series of caffeine-8-thioglycolic acid amides

Detalhes bibliográficos
Autor(a) principal: Kasabova-Angelova, Alexandra
Data de Publicação: 2020
Outros Autores: Kondeva-Burdina, Magdalena, Mitkov, Javor, Georgieva, Maya, Tzankova, Virginia, Zlatkov, Alexander
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Pharmaceutical Sciences
Texto Completo: https://www.revistas.usp.br/bjps/article/view/181445
Resumo: The effects of new derivatives of caffeine-8-thioglycolic acid (100 μM) on isolated rat brain synaptosomes, human neuroblastoma cell line SH-SY5Y and human recombinant MAOB enzyme (hMAOB) (1 μM) were evaluated. Most of the compounds, administered alone, didn’t show statistically significant neurotoxic effects on SH-SY5Y, when compared to the control (non-treated cells). Of all studied structures JTA-2Ox, JTA-11, JTA-12 and JTA-13 decreased cell viability. In combination with 6-hydroxydopamine (6-OHDA) (100 μM), only JTA-1 and JTA-2 revealed neuroprotective effects, stronger than those of caffeine. All compounds administered alone revealed, neurotoxic effects on synaptosomes, as compared to nontreated synaptosomes. JTA-1, JTA-2 and JTA-3 showed lowest neurotoxic effects and were investigated in a model of 6-OHDA-induced oxidative stress. In this model of neurotoxicity, only JTA-1 and JTA-2 showed statistically significant neuroprotective effect, by preserving the synaptosomal viability and the level of reduced glutathione. Inhibition of hMAOB, was revealed by JTA-1 and JTA-2. They inhibited the enzyme by 23% and 25% respectively, thus approaching the selegiline activity, which was 42%. The possible mechanisms of neuroprotection of JTA-1 and JTA-2 might be a result from the inhibition of hMAOB, which catalyze the production of neurotoxic p-quinone from 6-OHDA.
id USP-31_175ed9a6e9a69290e9c2727f186a56f3
oai_identifier_str oai:revistas.usp.br:article/181445
network_acronym_str USP-31
network_name_str Brazilian Journal of Pharmaceutical Sciences
repository_id_str
spelling Neuroprotective and MAOB inhibitory effects of a series of caffeine-8-thioglycolic acid amidesNeuroprotectionCaffeineSynaptosomesSH-SY5YhMAOBThe effects of new derivatives of caffeine-8-thioglycolic acid (100 μM) on isolated rat brain synaptosomes, human neuroblastoma cell line SH-SY5Y and human recombinant MAOB enzyme (hMAOB) (1 μM) were evaluated. Most of the compounds, administered alone, didn’t show statistically significant neurotoxic effects on SH-SY5Y, when compared to the control (non-treated cells). Of all studied structures JTA-2Ox, JTA-11, JTA-12 and JTA-13 decreased cell viability. In combination with 6-hydroxydopamine (6-OHDA) (100 μM), only JTA-1 and JTA-2 revealed neuroprotective effects, stronger than those of caffeine. All compounds administered alone revealed, neurotoxic effects on synaptosomes, as compared to nontreated synaptosomes. JTA-1, JTA-2 and JTA-3 showed lowest neurotoxic effects and were investigated in a model of 6-OHDA-induced oxidative stress. In this model of neurotoxicity, only JTA-1 and JTA-2 showed statistically significant neuroprotective effect, by preserving the synaptosomal viability and the level of reduced glutathione. Inhibition of hMAOB, was revealed by JTA-1 and JTA-2. They inhibited the enzyme by 23% and 25% respectively, thus approaching the selegiline activity, which was 42%. The possible mechanisms of neuroprotection of JTA-1 and JTA-2 might be a result from the inhibition of hMAOB, which catalyze the production of neurotoxic p-quinone from 6-OHDA.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2020-12-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/18144510.1590/s2175-97902019000318255Brazilian Journal of Pharmaceutical Sciences; Vol. 56 (2020); e18255 Brazilian Journal of Pharmaceutical Sciences; v. 56 (2020); e18255 Brazilian Journal of Pharmaceutical Sciences; Vol. 56 (2020); e18255 2175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/181445/168389Copyright (c) 2020 Brazilian Journal of Pharmaceutical Scienceshttp://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessKasabova-Angelova, Alexandra Kondeva-Burdina, Magdalena Mitkov, Javor Georgieva, Maya Tzankova, Virginia Zlatkov, Alexander 2021-06-12T19:46:54Zoai:revistas.usp.br:article/181445Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2021-06-12T19:46:54Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Neuroprotective and MAOB inhibitory effects of a series of caffeine-8-thioglycolic acid amides
title Neuroprotective and MAOB inhibitory effects of a series of caffeine-8-thioglycolic acid amides
spellingShingle Neuroprotective and MAOB inhibitory effects of a series of caffeine-8-thioglycolic acid amides
Kasabova-Angelova, Alexandra
Neuroprotection
Caffeine
Synaptosomes
SH-SY5Y
hMAOB
title_short Neuroprotective and MAOB inhibitory effects of a series of caffeine-8-thioglycolic acid amides
title_full Neuroprotective and MAOB inhibitory effects of a series of caffeine-8-thioglycolic acid amides
title_fullStr Neuroprotective and MAOB inhibitory effects of a series of caffeine-8-thioglycolic acid amides
title_full_unstemmed Neuroprotective and MAOB inhibitory effects of a series of caffeine-8-thioglycolic acid amides
title_sort Neuroprotective and MAOB inhibitory effects of a series of caffeine-8-thioglycolic acid amides
author Kasabova-Angelova, Alexandra
author_facet Kasabova-Angelova, Alexandra
Kondeva-Burdina, Magdalena
Mitkov, Javor
Georgieva, Maya
Tzankova, Virginia
Zlatkov, Alexander
author_role author
author2 Kondeva-Burdina, Magdalena
Mitkov, Javor
Georgieva, Maya
Tzankova, Virginia
Zlatkov, Alexander
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Kasabova-Angelova, Alexandra
Kondeva-Burdina, Magdalena
Mitkov, Javor
Georgieva, Maya
Tzankova, Virginia
Zlatkov, Alexander
dc.subject.por.fl_str_mv Neuroprotection
Caffeine
Synaptosomes
SH-SY5Y
hMAOB
topic Neuroprotection
Caffeine
Synaptosomes
SH-SY5Y
hMAOB
description The effects of new derivatives of caffeine-8-thioglycolic acid (100 μM) on isolated rat brain synaptosomes, human neuroblastoma cell line SH-SY5Y and human recombinant MAOB enzyme (hMAOB) (1 μM) were evaluated. Most of the compounds, administered alone, didn’t show statistically significant neurotoxic effects on SH-SY5Y, when compared to the control (non-treated cells). Of all studied structures JTA-2Ox, JTA-11, JTA-12 and JTA-13 decreased cell viability. In combination with 6-hydroxydopamine (6-OHDA) (100 μM), only JTA-1 and JTA-2 revealed neuroprotective effects, stronger than those of caffeine. All compounds administered alone revealed, neurotoxic effects on synaptosomes, as compared to nontreated synaptosomes. JTA-1, JTA-2 and JTA-3 showed lowest neurotoxic effects and were investigated in a model of 6-OHDA-induced oxidative stress. In this model of neurotoxicity, only JTA-1 and JTA-2 showed statistically significant neuroprotective effect, by preserving the synaptosomal viability and the level of reduced glutathione. Inhibition of hMAOB, was revealed by JTA-1 and JTA-2. They inhibited the enzyme by 23% and 25% respectively, thus approaching the selegiline activity, which was 42%. The possible mechanisms of neuroprotection of JTA-1 and JTA-2 might be a result from the inhibition of hMAOB, which catalyze the production of neurotoxic p-quinone from 6-OHDA.
publishDate 2020
dc.date.none.fl_str_mv 2020-12-09
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/bjps/article/view/181445
10.1590/s2175-97902019000318255
url https://www.revistas.usp.br/bjps/article/view/181445
identifier_str_mv 10.1590/s2175-97902019000318255
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/bjps/article/view/181445/168389
dc.rights.driver.fl_str_mv Copyright (c) 2020 Brazilian Journal of Pharmaceutical Sciences
http://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2020 Brazilian Journal of Pharmaceutical Sciences
http://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
dc.source.none.fl_str_mv Brazilian Journal of Pharmaceutical Sciences; Vol. 56 (2020); e18255
Brazilian Journal of Pharmaceutical Sciences; v. 56 (2020); e18255
Brazilian Journal of Pharmaceutical Sciences; Vol. 56 (2020); e18255
2175-9790
1984-8250
reponame:Brazilian Journal of Pharmaceutical Sciences
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Brazilian Journal of Pharmaceutical Sciences
collection Brazilian Journal of Pharmaceutical Sciences
repository.name.fl_str_mv Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)
repository.mail.fl_str_mv bjps@usp.br||elizabeth.igne@gmail.com
_version_ 1787713372380200960